Table 5.
The subgroup analysis of rs7837328 and cancer susceptibility
| Subgroup | No. | Homozygote
|
Heterozygote
|
Dominant model
|
Recessive model
|
Additive model
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | ||
| Ethnicity | 6 | ||||||||||
| Caucasian | 2 | 1.366 (1.084–1.721) | 0.008 | 1.266 (1.064–1.506) | 0.008 | 1.291 (1.096–1.521) | 0.002 | 1.188 (0.966–1.461) | 0.102 | 1.182 (1.058–1.321) | 0.003 |
| Asian | 4 | 1.328 (1.180–1.495) | <0.001 | 1.199 (1.109–1.295) | <0.001 | 1.226 (1.139–1.319) | <0.001 | 1.209 (1.082–1.351) | 0.001 | 1.166 (1.105–1.230) | <0.001 |
| Source | 6 | ||||||||||
| Population-based | 4 | 1.320 (1.187–1.469) | <0.001 | 1.210 (1.126–1.299) | <0.001 | 1.233 (1.152–1.319) | <0.001 | 1.188 (1.076–1.312) | 0.001 | 1.163 (1.108–1.222) | <0.001 |
| Hospital-based | 2 | 2.126 (1.077–4.195) | 0.030 | 1.207 (0.708–2.059) | 0.489 | 1.439 (0.876–2.363) | 0.151 | 1.960 (1.073–3.577) | 0.028 | 1.468 (1.047–2.057) | 0.026 |
| Method | 6 | ||||||||||
| Taqman | 2 | 2.126 (1.077–4.195) | 0.030 | 1.207 (0.708–2.059) | 0.489 | 1.439 (0.876–2.363) | 0.151 | 1.960 (1.073–1.073) | 0.028 | 1.468 (1.047–2.057) | 0.026 |
| Illumina | 1 | - | - | - | - | - | - | - | - | - | - |
| PCR | 1 | - | - | - | - | - | - | - | - | - | - |
| SNPlex | 1 | - | - | - | - | - | - | - | - | - | - |
| MassARRAY | 1 | - | - | - | - | - | - | - | - | - | - |
| Cancer | 6 | ||||||||||
| CRC | 2 | 1.360 (1.200–1.542) | <0.001 | 1.201 (1.107–1.302) | <0.001 | 1.232 (1.141–1.331) | <0.001 | 1.474 (0.873–2.488) | 0.146 | 1.260 (0.989–1.604) | 0.061 |
| pCa | 4 | 1.279 (1.054–1.553) | 0.013 | 1.238 (1.071–1.430) | 0.004 | 1.249 (1.090–1.432) | 0.001 | 1.127 (0.947–1.341) | 0.178 | 1.147 (1.045–1.258) | 0.004 |